Lack of Foxp3+ macrophages in both untreated and B16 melanoma-bearing mice.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2012-02-02
Metadata
Show full item recordThe following license files are associated with this item:
Related articles
- Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location.
- Authors: Kakinuma T, Nadiminti H, Lonsdorf AS, Murakami T, Perez BA, Kobayashi H, Finkelstein SE, Pothiawala G, Belkaid Y, Hwang ST
- Issue date: 2007 Jul
- Macrophages have no lineage history of Foxp3 expression.
- Authors: Put S, Avau A, Humblet-Baron S, Schurgers E, Liston A, Matthys P
- Issue date: 2012 Feb 2
- Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction.
- Authors: Niu J, Jiang C, Li C, Liu L, Li K, Jian Z, Gao T
- Issue date: 2011 Aug
- Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model.
- Authors: Foureau DM, McKillop IH, Jones CP, Amin A, White RL, Salo JC
- Issue date: 2011 Sep
- [Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice].
- Authors: Jiao YM, Zhang L, Ge YY, Liang YJ, Yong W
- Issue date: 2011 Jun